Generics Infringe On Branded Stock Growth As Investors Eye Mergers, Part D

Generic drug consolidation and the pending implementation of Medicare Part D in January, with its cost pressures likely to benefit unbranded drugs, appear to be swaying investor confidence in favor of generic drug makers